

# Rational design of carbonic anhydrase VII inhibitors. Synthesis of new candidates with the sulfamide scaffold



UNIVERSIDAD  
NACIONAL  
DE LA PLATA


Federico M. Garofalo, Karen A. Terrazas, Luciana Gavernet and Melisa E. Gantner

Laboratory of Bioactive Research and Development (LIDeB), Faculty of Exact Sciences, National University of La Plata (UNLP), La Plata, Buenos Aires, Argentina

## Introduction

Human carbonic anhydrase VII (hCA VII) constitutes a promising molecular target for the treatment of epileptic seizures and other central nervous system disorders (such as neuropathic pain) due to its almost exclusive expression in neurons.<sup>1</sup>


hCA VII, like all catalytically active anhydrases, is a metalloenzyme characterized by a zinc ion in the active site.<sup>1</sup> These enzymes catalyze the carbon dioxide to bicarbonate reversible hydration reaction<sup>1</sup>:




## Aim

Here we present the application of a fully validated molecular docking protocol<sup>1</sup> for the rational selection of the most promising N,N'-disubstituted sulfamides derivatives to be synthesized as potential new hCAVII inhibitors.


## Inhibitor design



## General features of the candidates




## Organic Synthesis<sup>2</sup>



## Biological Assays

*In vitro*  
Inhibition assay against hCAVII



*In vivo*  
Acute models of epilepsy in mice



## References

- 1) Gantner, M. E et al. Identification of New Carbonic Anhydrase VII Inhibitors by Structure-Based Virtual Screening. *J. Chem. Inf. Model.* 2022, 62 (19), 4760–4770. <https://doi.org/10.1021/acs.jcim.2c00910>.
- 2) Villalba, M. L et al *Bioorganic & Medicinal Chemistry* 2016, 24 (4), 894–901 <https://doi.org/10.1016/j.bmc.2016.01.012>

fgarofalo@quimica.unlp.edu.ar

ECMC  
2022

The 8th International Electronic  
Conference on Medicinal Chemistry  
01–30 NOVEMBER 2022 | ONLINE